Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Kyverna Therapeutics, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
kyvernatx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Kyverna Therapeutics announced positive one-year data from its registrational trial KYSA-8 for miv-cel in stiff person syndrome patients, along with favorable long-term follow-up data from the Phase 2 KYSA-6 trial in generalized myasthenia gravis patients, marking significant clinical development milestones.
Key Takeaways
One-year data from registrational trial KYSA-8 demonstrates positive efficacy and safety for miv-cel in stiff person syndrome
Long-term follow-up data from Phase 2 trial KYSA-6 shows favorable results in generalized myasthenia gravis patients
2 more takeaways
Filing Overview
What This Means
Kyverna Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.